This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05931367 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 445 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight; Osteo Arthritis Knee |
| Interventions | Retatrutide; Placebo |
| Start | Aug 1, 2023 |
| Primary completion | Nov 14, 2025 |
| Study completion | Nov 14, 2025 |
| Results posted | Not yet |
| Registry last updated | Jan 21, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score | Baseline, Week 68 |
| Percent Change from Baseline in Body Weight | Baseline, Week 68 |
11 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
